Filing Flows › Health Care › Theriva Biologics (TOVX)
Theriva Biologics (TOVX) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 5, 2026 · Theriva Biologics (TOVX) Q1 2026 earnings results →
Q1 2026 681¢ of every $1 of revenue lost · operating margin -709.0%
Theriva Biologics made $300K in Q1 2026. Operating margin -709.0%, net loss $2.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $300K in Q1 2026.
Operating costs exceeded revenue by $2.1M, an operating margin of -709.0%. The quarter ended with a net loss of $2.0M.
Operating cash flow was −$2.5M. Non-cash charges added back $24K of depreciation and amortization and $135K of share-based compensation. Working capital and other items used $571K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 5, 2026 | $300K | — | -709.0% | −$2.0M | −$2.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Theriva Biologics
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L. (“VCN”, formerly named VCN Biosciences, S.L.), in March 2022, as described in more detail below (the “Acquisition”), we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase.
In its own words, from its 10-K, filed Mar 12, 2026.
Theriva Biologics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -709.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TOVX Theriva Biologics | Q1 2026 | $300K | — | -709.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Theriva Biologics 10-Q on SEC EDGAR · CIK 894158 · Pharmaceutical Preparations
13F: who owns TOVX and who is buying
More on TOVX
History
Every quarter: Q1 2026 results